Chopas James George — SEC Form 4 filings
SEC reporting owner CIK 1836430. 18 Form 4 filings on record with FilingPulse; latest filed 2026-05-14.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-01-17 to 2026-05-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 14 legs across 14 filings — 10,028 shares, $346,148 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 1,061 shares @ $65.00 ($68,961) in Apellis Pharmaceuticals, Inc., filed 2024-01-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | VP/Chief Accounting Officer | 18 | — | 14 legs · 10,028 sh · $346,148 | 25 |
Form 4 filings — Chopas James George
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Code (U): 65,955 · Grant/award (A): 5,625 · Disposition to issuer (D): 5,625 · Grant/award (A): 8,394 · Disposition to issuer (D): 8,394 · Grant/award (A): 16,150 · +13 more | EDGAR |
| 2026-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 16,150 @ $0 | EDGAR |
| 2026-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,064 @ $21.77 | EDGAR |
| 2026-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 726 @ $19.79 | EDGAR |
| 2026-01-15 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 873 @ $22.19 | EDGAR |
| 2025-09-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 189 @ $24.19 | EDGAR |
| 2025-09-03 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 548 @ $28.08 | EDGAR |
| 2025-06-20 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 6,250 @ $0 | EDGAR |
| 2025-06-11 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 11,250 (derivative) @ $19.39 | EDGAR |
| 2025-03-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 183 @ $24.82 | EDGAR |
| 2025-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,096 @ $30.43 | EDGAR |
| 2025-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 715 @ $29.96 · Grant/award (A): 12,591 @ $0 | EDGAR |
| 2025-01-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 783 @ $28.70 | EDGAR |
| 2024-09-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 192 @ $36.21 | EDGAR |
| 2024-09-04 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 550 @ $39.49 | EDGAR |
| 2024-03-18 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 184 @ $56.46 | EDGAR |
| 2024-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 1,061 @ $65.00 | EDGAR |
| 2024-01-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 8,312 @ $0 · Sale (S): 864 @ $66.81 · Grant/award (A): 12,086 (derivative) @ $66.30 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1836430 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →